In a trial, Gossamer Bio's PAH treatment candidate seralutinib reduced the resistance blood faces moving into the lungs over ...

Advanced therapies, medicines bring new hope for pulmonary hypertension patients: Dr Manisha Mendiratta: Shardul Nautiyal, Mumbai Saturday, February 8, 2025, 08:00 Hrs [IST] Dr Ma ...

Natco Pharma gains FDA approval for generic Bosentan tablets, partnering with Lupin Pharmaceuticals for U.S. marketing.

Patients with chronic obstructive pulmonary disease, interstitial lung disease and pulmonary hypertension experience improved ...

Safety of a Potential New Treatment to Manage Complications from Sickle Cell Disease Apr. 11, 2024 — A drug approved to treat pulmonary arterial hypertension may be effective at managing ...

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and ...

The HYPERION study was evaluating Winrevair in recently diagnosed adults with pulmonary arterial hypertension.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the ...

Tectonic Therapeutic has done well to advance its Fc-fusion protein candidate TX45 into a phase 2 study targeting patients ...

Receiving a diagnosis for any disease/condition is not an easy experience. One organization hopes to make patients newly ...

Shares of Tectonic Therapeutic, Inc. (NASDAQ: TECX) surged 40% following the announcement of encouraging interim data from a Phase 1b trial for its TX45 treatment in patients with Group 2 Pulmonary ...

Although several Group 1 PH (Pulmonary Arterial Hypertension, “PAH”) medications have been explored in Group 2 PH, to date, no medications have been approved for its treatment. About TX45, a ...